Arthritis Medical Clinic
Arthritis Medical Clinic was paid $5.58M by Medicaid between Jan 2018 and Nov 2024, across 29 billing codes. Its largest line is 99215, doctor's office visit, returning patient (complex) — 52% of everything it billed.
33Billing provider infoARTHRITIS MEDICAL CLINIC
RIVERSIDE, CA 92506
RIVERSIDE, CA 92506
33aNPI1245255124assigned 07/13/2006
33bProvider typeSpecialist
28Total paid$5.58M
24GClaims58,518
24DCodes billed29
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Specialist providers in California
Rank by total paid#44 of 1,230
Median peer was paid$51K
This provider vs. median109×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,369 | $576K | |
| 2019 | 6,900 | $644K | |
| 2020 | 6,481 | $595K | |
| 2021 | 7,515 | $802K | |
| 2022 | 8,281 | $925K | |
| 2023 | 12,341 | $1.03M | |
| 2024incomplete | 11,631 | $1.01M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 52% | 17,471 | 16,842 | $2.92M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 13% | 7,706 | 7,422 | $743K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 11% | 4,637 | 4,252 | $588K |
| 99205 | Prolong outpt/office vis | 8.0% | 2,060 | 2,053 | $444K |
| 20610 | 4.6% | 3,586 | 3,218 | $256K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 3.4% | 1,151 | 1,141 | $189K |
| 96411 | 2.3% | 2,330 | 2,136 | $131K | |
| 96415 | 1.7% | 2,398 | 2,164 | $98K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 4,489 | 4,094 | $65K |
| 77080 | <1% | 1,426 | 1,422 | $46K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,417 | 1,413 | $27K |
| 20611 | <1% | 168 | 106 | $17K |
17 more codes
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,453 | $12K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,104 | $10K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,892 | $8K |
| 96401 | <1% | 201 | $8K | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 366 | $5K |
| 20605 | <1% | 87 | $5K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 418 | $4K |
| 99406 | <1% | 163 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,300 | $1K |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 246 | $909.81 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 12 | $825.50 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 166 | $674.75 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 108 | $584.85 |
| J0897 | Injection, denosumab, 1 mg | <1% | 65 | $463.01 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 35 | $167.41 |
| 99072 | <1% | 22 | $15.00 | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZAMIRI, BABAK (PRESIDENT)